<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03644108</url>
  </required_header>
  <id_info>
    <org_study_id>2009-GGE-04</org_study_id>
    <nct_id>NCT03644108</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics of Mucinex 600 mg Extended-release Bi-layer Tablet in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Open-label, Single-dose, Single-Period Study to Evaluate the Pharmacokinetics of Mucinex® 600 mg Extended-Release Bi-layer Tablet in Normal Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reckitt Benckiser Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reckitt Benckiser LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the Pharmacokinetics of Mucinex® 600 mg Extended-Release Bi-Layer Tablet in Normal
      Healthy Subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2009</start_date>
  <completion_date type="Actual">June 15, 2009</completion_date>
  <primary_completion_date type="Actual">June 15, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Guaifenesin</measure>
    <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
    <description>Pharmacokinetic Parameters Cmax (Maximum observed drug concentration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC(0-t)) of Guaifenesin</measure>
    <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
    <description>Area under the drug concentration-time curve calculated using linear trapezoidal summation from time zero to time t, where t is the time of the last measurable concentration (Ct).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC(0-inf)) of Guaifenesin</measure>
    <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
    <description>Area under the drug concentration-time curve from time zero to infinity, AUC(0-inf) = AUC(0-t) + Ct/Kel, where Kel is the terminal elimination rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) of Guaifenesin</measure>
    <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
    <description>Pharmacokinetic Parameter tmax (Time of the maximum observed drug concentration).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Plasma Concentration Curve Ratio (AUCR) of Guaifenesin</measure>
    <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
    <description>Ratio of AUC(0-t) to AUC(0-inf), referred to as AUCR. [AUCR = AUC(0-t) / AUC(0-inf)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Rate Constant (Kel) of Guaifenesin</measure>
    <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
    <description>Apparent terminal elimination rate constant (Kel) calculated by linear regression of the terminal linear portion of the log concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Half-life (t1/2) of Guaifenesin</measure>
    <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
    <description>Apparent terminal elimination half-life (t1/2) calculated as ln(2)/Kel.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Intensity was determined by the Investigator. For symptomatic AEs the following definitions were applied.
Mild = AE did not limit usual activities; subject may have experienced slight discomfort.
Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort.
Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain.
Relationship to Investigational Medicinal Products (IMP)
Unlikely = Slight, but remote, chance that AE was caused by IMP. Possible = Reasonable suspicion that the AE was caused by IMP. Probable = Most likely that AE was caused by IMP.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Mucinex® ER 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet taken with 240 mL of water after an overnight fast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mucinex® ER 600 mg</intervention_name>
    <description>Single dose of Mucinex® 600 mg ER Bi-Layer tablet</description>
    <arm_group_label>Mucinex® ER 600 mg</arm_group_label>
    <other_name>guaifenesin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and/or females between the ages of 19 and 55 years, inclusive.

          2. Females of childbearing potential must have been using 1 of the following acceptable
             birth control methods:

               1. Intra-uterine device (IUD) in place for at least 3 months prior to Day 1 through
                  30 days beyond study completion or first menstrual period.

               2. Barrier method (condom or diaphragm) with spermicide for at least 7 days prior to
                  screening through 30 days beyond study completion or first menstrual period
                  (whichever is longer).

               3. Stable hormonal contraceptive (e.g., PO, depo injection, transdermal patch, or
                  vaginal ring) for at least 3 months prior to Day 1 through 30 days beyond
                  completion of study or first menstrual period.

             Note: Abstinence is not an acceptable form of contraception; however, abstinent female
             subjects may have been admitted to the study if they agreed, and signed a statement to
             the effect, that upon becoming sexually active, would use a condom with spermicide
             from screening through 30 days beyond completion of the study.

          3. Females of non-childbearing potential must have been surgically sterile (bilateral
             tubal ligation with surgery at least 6 months prior to Day 1 or hysterectomy and/or
             bilateral oophorectomy at least 3 months prior to Day 1) or postmenopausal &gt;2 years
             prior to Day 1. A follicle stimulating hormone (FSH) level &gt;40 miU/mL must be obtained
             and recorded for any postmenopausal females.

          4. Good general health as determined by the PI's review of medical history, physical
             examination, vital sign measurements, electrocardiogram (ECG), and clinical laboratory
             measures.

          5. Within 15% of ideal body weight (Table of 'Desirable Weights of Adults' Metropolitan
             Life Insurance Company, 1983).

          6. Non-tobacco users, who had not used nicotine or nicotine-containing products for at
             least 365 days prior to Day 1.

          7. Able to read, understand, and sign the informed consent form (ICF), after the nature
             of the study had been explained.

          8. Negative urine screen for drugs of abuse and alcohol at screening and each check-in.

          9. If female, negative finding on serum pregnancy test at screening and each check-in.

        Exclusion Criteria:

          1. Clinically significant abnormalities detected by medical history, physical
             examination, vital sign measurements, ECG, or clinical laboratory findings (as
             determined by the PI/designee) including a hemoglobin value &lt;12 g/dL at screening. If
             a subject's hemoglobin drops below 11.0 g/dL during the study, the subject may be
             dropped from the study at the discretion of the PI.

          2. Any disease or condition that could impact absorption, distribution, metabolism, or
             elimination of the study drugs (as determined by the PI/designee).

          3. Alcoholism or medicinal product or drug abuse within the past 2 years or excessive
             alcohol consumption (more than 10 units per week) (1 unit is defined as 5 ounces of
             wine, 12 ounces of beer, or 1.5 ounces of spirits (i.e., 'hard' liquor such as gin,
             whiskey, or vodka, et. al.). The subject could not experience tolerance, withdrawal,
             compulsive use, or substance related problems such as medical complications,
             disruption in social and family relationships, vocational or financial difficulties,
             or legal problems.

          4. Females who were pregnant or nursing.

          5. History of hypersensitivity reaction to guaifenesin.

          6. Receipt of an investigational drug within 30 days prior to Day 1.

          7. Abnormal diet (for whatever reason) during the 30 days prior to Day 1.

          8. Donation of blood or significant loss of blood within 56 days or plasma within 14 days
             prior to Day 1.

          9. Known or suspected use of illicit drugs.

         10. The use of any medication (with the exception of hormonal contraceptives for women of
             childbearing potential) for 14 days or 5 half-lives of the drug (whichever is longer)
             prior to Day 1.

         11. Test positive for Hepatitis B surface antigen, Hepatitis C antibodies, or human
             immunodeficiency virus (HIV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <results_first_submitted>September 18, 2018</results_first_submitted>
  <results_first_submitted_qc>February 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2019</results_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guaifenesin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a single-centre study.</recruitment_details>
      <pre_assignment_details>A total of 30 subjects were screened for the study; All 30 subjects were included single-period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mucinex® 600 mg ER</title>
          <description>Single dose Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet expectorant by mouth.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mucinex® 600 mg ER</title>
          <description>Single dose Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet expectorant by mouth.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>lb</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160.4" spread="23.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>in</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.41" spread="3.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.976" spread="1.8368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Guaifenesin</title>
        <description>Pharmacokinetic Parameters Cmax (Maximum observed drug concentration)</description>
        <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
        <population>Data Sets Analyzed as all 30 subjects were included in the guaifenesin concentration tables and the calculation of guaifenesin Pharmacokinetic (PK) parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Mucinex® 600 mg ER</title>
            <description>Single dose Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet expectorant by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Guaifenesin</title>
          <description>Pharmacokinetic Parameters Cmax (Maximum observed drug concentration)</description>
          <population>Data Sets Analyzed as all 30 subjects were included in the guaifenesin concentration tables and the calculation of guaifenesin Pharmacokinetic (PK) parameters.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="876" spread="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC(0-t)) of Guaifenesin</title>
        <description>Area under the drug concentration-time curve calculated using linear trapezoidal summation from time zero to time t, where t is the time of the last measurable concentration (Ct).</description>
        <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mucinex® 600 mg ER</title>
            <description>Single dose Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet expectorant by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC(0-t)) of Guaifenesin</title>
          <description>Area under the drug concentration-time curve calculated using linear trapezoidal summation from time zero to time t, where t is the time of the last measurable concentration (Ct).</description>
          <units>ng∙hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3670" spread="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC(0-inf)) of Guaifenesin</title>
        <description>Area under the drug concentration-time curve from time zero to infinity, AUC(0-inf) = AUC(0-t) + Ct/Kel, where Kel is the terminal elimination rate constant.</description>
        <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mucinex® 600 mg ER</title>
            <description>Single dose Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet expectorant by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC(0-inf)) of Guaifenesin</title>
          <description>Area under the drug concentration-time curve from time zero to infinity, AUC(0-inf) = AUC(0-t) + Ct/Kel, where Kel is the terminal elimination rate constant.</description>
          <units>ng∙hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3694" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Observed Concentration (Tmax) of Guaifenesin</title>
        <description>Pharmacokinetic Parameter tmax (Time of the maximum observed drug concentration).</description>
        <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mucinex® 600 mg ER</title>
            <description>Single dose Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet expectorant by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration (Tmax) of Guaifenesin</title>
          <description>Pharmacokinetic Parameter tmax (Time of the maximum observed drug concentration).</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.752" lower_limit="0.498" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under Plasma Concentration Curve Ratio (AUCR) of Guaifenesin</title>
        <description>Ratio of AUC(0-t) to AUC(0-inf), referred to as AUCR. [AUCR = AUC(0-t) / AUC(0-inf)]</description>
        <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mucinex® 600 mg ER</title>
            <description>Single dose Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet expectorant by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration Curve Ratio (AUCR) of Guaifenesin</title>
          <description>Ratio of AUC(0-t) to AUC(0-inf), referred to as AUCR. [AUCR = AUC(0-t) / AUC(0-inf)]</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9934" spread="0.007125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Elimination Rate Constant (Kel) of Guaifenesin</title>
        <description>Apparent terminal elimination rate constant (Kel) calculated by linear regression of the terminal linear portion of the log concentration-time curve.</description>
        <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mucinex® 600 mg ER</title>
            <description>Single dose Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet expectorant by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Rate Constant (Kel) of Guaifenesin</title>
          <description>Apparent terminal elimination rate constant (Kel) calculated by linear regression of the terminal linear portion of the log concentration-time curve.</description>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.455" spread="0.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Elimination Half-life (t1/2) of Guaifenesin</title>
        <description>Apparent terminal elimination half-life (t1/2) calculated as ln(2)/Kel.</description>
        <time_frame>0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16 and 24 hours (post-dose) on Day 1 and 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mucinex® 600 mg ER</title>
            <description>Single dose Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet expectorant by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Half-life (t1/2) of Guaifenesin</title>
          <description>Apparent terminal elimination half-life (t1/2) calculated as ln(2)/Kel.</description>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment Emergent Adverse Events (TEAEs)</title>
        <description>Intensity was determined by the Investigator. For symptomatic AEs the following definitions were applied.
Mild = AE did not limit usual activities; subject may have experienced slight discomfort.
Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort.
Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain.
Relationship to Investigational Medicinal Products (IMP)
Unlikely = Slight, but remote, chance that AE was caused by IMP. Possible = Reasonable suspicion that the AE was caused by IMP. Probable = Most likely that AE was caused by IMP.</description>
        <time_frame>Up to Day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mucinex® 600 mg ER</title>
            <description>Single dose Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet expectorant by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment Emergent Adverse Events (TEAEs)</title>
          <description>Intensity was determined by the Investigator. For symptomatic AEs the following definitions were applied.
Mild = AE did not limit usual activities; subject may have experienced slight discomfort.
Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort.
Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain.
Relationship to Investigational Medicinal Products (IMP)
Unlikely = Slight, but remote, chance that AE was caused by IMP. Possible = Reasonable suspicion that the AE was caused by IMP. Probable = Most likely that AE was caused by IMP.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE by severity: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP - Unlikely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Possible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 2</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mucinex® 600 mg ER</title>
          <description>Single dose Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet expectorant by mouth.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Director, Clinical Research</name_or_title>
      <organization>Reckitt Benckiser, Inc</organization>
      <email>clinicalrequests@rb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

